Beam Therapeutics BEAM Common stock issuance for private placement
Common stock issuance for private placement at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPrivatePlacement.
The official record: Beam Therapeutics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's common stock issuance for private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's common stock issuance for private placement?
- Beam Therapeutics (BEAM) reported common stock issuance for private placement of $0 in Q4 2025.
- What is the long-term trend for Beam Therapeutics's common stock issuance for private placement?
- Over 2 years (2023 to 2025), Beam Therapeutics's common stock issuance for private placement has grown at a -100.0% compound annual growth rate (CAGR), from $33.6M to $0.
- What does common stock issuance for private placement mean?
- Represents the cash inflows generated from the sale of equity or debt securities to a select group of private investors. This is a primary mechanism for biotechnology companies to raise capital without the regulatory burden of a public offering. It indicates the company's ability to secure funding from institutional or strategic partners to support ongoing operations.